Literature DB >> 30336956

Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment.

Terufumi Kawamoto1, Naoto Shikama2, Keisuke Sasai3.   

Abstract

Entities:  

Keywords:  Metastatic breast cancer; Palbociclib; Radiation induced enterocolitis; Radiotherapy

Mesh：

Substances：

Year:  2018        PMID： 30336956     DOI： 10.1016/j.radonc.2018.09.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  13 in total

1.  CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.

Authors:  Nicholas B Figura; Thrisha K Potluri; Homan Mohammadi; Daniel E Oliver; John A Arrington; Timothy J Robinson; Arnold B Etame; Nam D Tran; James K Liu; Hatem Soliman; Peter A Forsyth; Solmaz Sahebjam; H Michael Yu; Hyo S Han; Kamran A Ahmed
Journal:  J Neurooncol       Date:  2019-08-09       Impact factor: 4.130

Review 2.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

3.  Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report.

Authors:  Jay A Messer; Ekim Ekinci; Tejal A Patel; Bin S Teh
Journal:  Rep Pract Oncol Radiother       Date:  2019-03-20

4.  Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.

Authors:  Andrea M Pesch; Nicole H Hirsh; Benjamin C Chandler; Anna R Michmerhuizen; Cassandra L Ritter; Marlie P Androsiglio; Kari Wilder-Romans; Meilan Liu; Christina L Gersch; José M Larios; Lori J Pierce; James M Rae; Corey W Speers
Journal:  Clin Cancer Res       Date:  2020-09-23       Impact factor: 12.531

Review 5.  Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.

Authors:  Ambrogio Gagliano; Angela Prestifilippo; Ornella Cantale; Gianluca Ferini; Giacomo Fisichella; Paolo Fontana; Dorotea Sciacca; Dario Giuffrida
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

6.  A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.

Authors:  Andrea Emanuele Guerini; Sara Pedretti; Emiliano Salah; Edda Lucia Simoncini; Marta Maddalo; Ludovica Pegurri; Rebecca Pedersini; Lucia Vassalli; Nadia Pasinetti; Gloria Peretto; Luca Triggiani; Gianluca Costantino; Vanessa Figlia; Filippo Alongi; Stefano Maria Magrini; Michela Buglione
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

Review 7.  CDK4/6 inhibitors: a novel strategy for tumor radiosensitization.

Authors:  Yilan Yang; Jurui Luo; Xingxing Chen; Zhaozhi Yang; Xin Mei; Jinli Ma; Zhen Zhang; Xiaomao Guo; Xiaoli Yu
Journal:  J Exp Clin Cancer Res       Date:  2020-09-15

8.  [Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].

Authors:  David Krug; Alexander Fabian; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-03       Impact factor: 3.621

Review 9.  The role of radiation therapy and systemic therapies in elderly with breast cancer.

Authors:  Valerio Nardone; Sara Falivene; Francesca Maria Giugliano; Marcella Gaetano; Pasqualina Giordano; Matteo Muto; Bruno Daniele; Cesare Guida
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

10.  Novel Combinatorial Strategy Using Thermal Inkjet Bioprinting, Chemotherapy, and Radiation on Human Breast Cancer Cells; an In-Vitro Cell Viability Assessment.

Authors:  Aleli Campbell; Denisse A Gutierrez; Colin Knight; Charlotte M Vines; Rosalinda Heydarian; Alexander Philipovskiy; Armando Varela-Ramirez; Thomas Boland
Journal:  Materials (Basel)       Date:  2021-12-19       Impact factor: 3.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.